2 weeks Ago By ABMN Staff
Amgen Inc. ( NASDAQ:AMGN – Get Free Report ) was the target of a large growth in short interest during the month of September. As of September 15th, there was short interest totalling 9,000,000 shares, a growth of 6.
1% from the August 31st total of 8,480,000 shares. Currently, 1.7% of the shares of the company are sold short.
Based on an average trading volume of 1,990,000 shares, the days-to-cover ratio is currently 4.5 days. Analyst Ratings Changes A number of brokerages have issued reports on AMGN.
TD Cowen boosted their price target on Amgen from $360.00 to $381.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th.
Dbs Bank raised Amgen to a “strong-buy” rating in a research report on Monday, September 16th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $362.00 target price on shares of Amgen in a research report on Thursday, September 26th.
Bank of America upped their price target on Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th.
Finally, Oppenheimer restated an “outperform” rating and set a $380.00 target price on shares of Amgen in a research note on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock.
According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $325.55.
View Our Latest Research Report on AMGN Hedge Funds Weigh In On Amgen Amgen Trading Down 0.1 % NASDAQ AMGN opened at $322.21 on Tuesday.
The company has a market cap of $172.84 billion, a price-to-earnings ratio of 46.03, a P/E/G ratio of 2.
98 and a beta of 0.61. Amgen has a 52 week low of $249.
70 and a 52 week high of $346.85. The business has a 50 day moving average price of $328.
49 and a 200-day moving average price of $308.12. The company has a quick ratio of 0.
89, a current ratio of 1.26 and a debt-to-equity ratio of 9.64.
Amgen ( NASDAQ:AMGN – Get Free Report ) last announced its earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.
01 by ($0.04). Amgen had a net margin of 10.
12% and a return on equity of 161.72%. The company had revenue of $8.
39 billion for the quarter, compared to analysts’ expectations of $8.35 billion. During the same period in the previous year, the firm earned $5.
00 EPS. The firm’s quarterly revenue was up 20.1% on a year-over-year basis.
As a group, equities analysts expect that Amgen will post 19.49 earnings per share for the current fiscal year. Amgen Dividend Announcement The business also recently disclosed a quarterly dividend, which was paid on Tuesday, August 6th.
Investors of record on Friday, August 16th were paid a dividend of $2.25 per share. The ex-dividend date was Friday, August 16th.
This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.79%.
Amgen’s payout ratio is 128.57%. About Amgen ( Get Free Report ) Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide.
The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. Featured Stories Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter .
.
